Related Experiment Video
Updated: May 19, 2026

Electrochemiluminescence Assays for Human Islet Autoantibodies
Published on: March 23, 2018
Diurnal Variation of Islet Autoantibody Titers in Established Type 1 Diabetes Suggests Restricted-Time Sampling
Craig Beam1, Linda DiMeglio2, Cate Speake3
1Homer Stryker MD School of Medicine, Western Michigan University.
Abstract:
Diurnal Variation of Islet Autoantibody Titers in Established Type 1 Diabetes Suggests Restricted-Time Sampling Improves Aab Measurement and Detection Diurnal islet autoantibody (Aab) variation in type 1 diabetes (T1D) remains poorly understood and could hinder efforts to develop, test and refine new therapies. We sought to describe the extent and pattern of diurnal variation in islet autoantibodies and, having found significant variation, translate to the clinical setting. We conducted two studies in human subjects with established T1D: (1) a prospective study (n = 10) of the range of islet autoantibody and immunoglobulin daily variation within humans and (2) an independent retrospective, cross-sectional study (n = 705) of the effect of time of sample collection on Aab titer and detection in clinical settings. We found that some individuals have wide Aab variations during the day and which can exceed expected levels of inter-assay variation. For some Aab, this variation followed a circadian pattern. We also found that, in clinical settings, time-restricted sampling can lead to increased IA-2A and ZnT8A detection within specific age-groups. We conclude that time-restriction can potentially improve the use of Radiobinding-measured Aabs as biomarkers for the development and monitoring of disease-modifying therapies and in developing islet transplantation strategies in established T1D. Investigation of diurnal Aab variation and time restriction is needed in early-stage disease.
More Related Videos
Related Concept Videos
Type I Diabetes I: Introduction
Type I Diabetes II: Pathophysiology
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes III: Clinical Manifestations

